-
Something wrong with this record ?
Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats
E. Drazanova, L. Kratka, N. Vaskovicova, R. Skoupy, K. Horska, Z. Babinska, H. Kotolova, L. Vrlikova, M. Buchtova, Z. Starcuk, J. Ruda-Kucerova,
Language English Country Switzerland
Document type Journal Article
Grant support
NV16-30299A
MZ0
CEP Register
- MeSH
- Antipsychotic Agents administration & dosage adverse effects MeSH
- Magnetic Resonance Imaging MeSH
- Cerebrovascular Circulation drug effects MeSH
- Olanzapine administration & dosage adverse effects MeSH
- Rats, Sprague-Dawley MeSH
- Drug Administration Schedule MeSH
- Sensorimotor Cortex blood supply diagnostic imaging drug effects MeSH
- Organ Size drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Olanzapine is a frequently used atypical antipsychotic drug known to exert structural brain alterations in animals. This study investigated whether chronic olanzapine exposure alters regional blood brain perfusion assessed by Arterial Spin Labelling (ASL) magnetic resonance imaging (MRI) in a validated model of olanzapine-induced metabolic disturbances. An effect of acute olanzapine exposure on brain perfusion was also assessed for comparison. METHODS: Adult Sprague-Dawley female rats were treated by intramuscular depot olanzapine injections (100 mg/kg every 14 days) or vehicle for 8 weeks. ASL scanning was performed on a 9.4 T Bruker BioSpec 94/30USR scanner under isoflurane anesthesia. Serum samples were used to assay leptin and TNF-α level while brains were sliced for histology. Another group received only one non-depot intraperitoneal dose of olanzapine (7 mg/kg) during MRI scanning, thus exposing its acute effect on brain perfusion. RESULTS: Both acute and chronic dosing of olanzapine resulted in decreased perfusion in the sensorimotor cortex, while no effect was observed in the piriform cortex or hippocampus. Furthermore, in the chronically treated group decreased cortex volume was observed. Chronic olanzapine dosing led to increased body weight, adipose tissue mass and leptin level, confirming its expected metabolic effects. CONCLUSION: This study demonstrates region-specific decreases in blood perfusion associated with olanzapine exposure present already after the first dose. These findings extend our understanding of olanzapine-induced functional and structural brain changes.
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
Institute of Scientific Instruments of the Czech Academy of Sciences Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023655
- 003
- CZ-PrNML
- 005
- 20201214130733.0
- 007
- ta
- 008
- 201125s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pharep.2019.04.020 $2 doi
- 035 __
- $a (PubMed)31394417
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Drazanova, Eva $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic. Electronic address: edrazan@isibrno.cz.
- 245 10
- $a Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats / $c E. Drazanova, L. Kratka, N. Vaskovicova, R. Skoupy, K. Horska, Z. Babinska, H. Kotolova, L. Vrlikova, M. Buchtova, Z. Starcuk, J. Ruda-Kucerova,
- 520 9_
- $a BACKGROUND: Olanzapine is a frequently used atypical antipsychotic drug known to exert structural brain alterations in animals. This study investigated whether chronic olanzapine exposure alters regional blood brain perfusion assessed by Arterial Spin Labelling (ASL) magnetic resonance imaging (MRI) in a validated model of olanzapine-induced metabolic disturbances. An effect of acute olanzapine exposure on brain perfusion was also assessed for comparison. METHODS: Adult Sprague-Dawley female rats were treated by intramuscular depot olanzapine injections (100 mg/kg every 14 days) or vehicle for 8 weeks. ASL scanning was performed on a 9.4 T Bruker BioSpec 94/30USR scanner under isoflurane anesthesia. Serum samples were used to assay leptin and TNF-α level while brains were sliced for histology. Another group received only one non-depot intraperitoneal dose of olanzapine (7 mg/kg) during MRI scanning, thus exposing its acute effect on brain perfusion. RESULTS: Both acute and chronic dosing of olanzapine resulted in decreased perfusion in the sensorimotor cortex, while no effect was observed in the piriform cortex or hippocampus. Furthermore, in the chronically treated group decreased cortex volume was observed. Chronic olanzapine dosing led to increased body weight, adipose tissue mass and leptin level, confirming its expected metabolic effects. CONCLUSION: This study demonstrates region-specific decreases in blood perfusion associated with olanzapine exposure present already after the first dose. These findings extend our understanding of olanzapine-induced functional and structural brain changes.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antipsychotika $x aplikace a dávkování $x škodlivé účinky $7 D014150
- 650 _2
- $a mozkový krevní oběh $x účinky léků $7 D002560
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a olanzapin $x aplikace a dávkování $x škodlivé účinky $7 D000077152
- 650 _2
- $a velikost orgánu $x účinky léků $7 D009929
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a senzorimotorický kortex $x krevní zásobení $x diagnostické zobrazování $x účinky léků $7 D066191
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kratka, Lucie $u Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Vaskovicova, Nadezda $u Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Skoupy, Radim $u Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Horska, Katerina $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
- 700 1_
- $a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Kotolova, Hana $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
- 700 1_
- $a Vrlikova, Lucie $u Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
- 700 1_
- $a Buchtova, Marcela $u Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Brno, Czech Republic.
- 700 1_
- $a Starcuk, Zenon $u Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
- 700 1_
- $a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 773 0_
- $w MED00165879 $t Pharmacological reports : PR $x 1734-1140 $g Roč. 71, č. 5 (2019), s. 839-847
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31394417 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130732 $b ABA008
- 999 __
- $a ok $b bmc $g 1595974 $s 1114331
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 71 $c 5 $d 839-847 $e 20190504 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
- GRA __
- $a NV16-30299A $p MZ0
- LZP __
- $a Pubmed-20201125
